Premium
Lymphoma models for B cell activation and tolerance IV. Growth inhibition by anti‐Ig of CH31 and CH33 B lymphoma cells
Author(s) -
Pennell Christopher A.,
Scott David W.
Publication year - 1986
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830161217
Subject(s) - biology , idiotype , polyclonal antibodies , antiserum , monoclonal antibody , lymphoma , antibody , microbiology and biotechnology , major histocompatibility complex , b cell , antigen , growth inhibition , in vitro , cancer research , immunology , biochemistry
Abstract CH31 and CH33 are B cell lymphomas whose growth in vitro is inhibited by anti‐Ig reagents, including both polyclonal and monoclonal anti‐μ antibodies, and an anti‐idiotype antiserum. Antibodies against class I or class II major histocompatibility complex antigens do not affect the growth of these cells. Inhibition is dependent on surface Ig cross‐linking and does not require ligand binding to Fc receptors. Interestingly, the inhibition of growth by anti‐μ, is reversed in CH31 (but not CH33) by E. coli lipopolysaccharide. These lymphomas should provide excellent models to study the mechanisms of growth inhibition mediated by surface Ig cross‐linking and the pathways of its reversal.